Systemic lupus erythematosus: Clinical features in patients with a disease duration of over 10 years, first evaluation

Rheumatology

Volumn 38, Issue 10, 1999, Pages 953-958

  Swaak, A J G ^a   Van Den Brink, H G ^b   Smeenk, R J T ^b   Manger, K ^b   Kalden, J R ^b   Tosi, S ^b   Marchesoni, A ^b   Domljan, Z ^b   Rozman, B ^b   Logar, D ^b   Pokorny, G ^b   Kovacs, L ^b   Kovacs, A ^b   Vlachoyiannopoulos, P G ^b   Moutsopoulos, H M ^b   Chwalinska Sadowska, H ^b   Dratwianka, B ^b   Kiss, E ^b   Cikes, N ^b   Branimir, A ^b   Schneider, M ^b   Fischer, R ^b   Bombardieri, S ^b   Mosca, M ^b   Graninger, W ^b   Smolen, J S ^b   more..

^a Zuiderziekenhuis   (Netherlands)

^b NONE

Author keywords

Damage Index; Disease activity; ECLAM; SLE; SLEDAI

Indexed keywords

PREDNISOLONE;

ADULT; ARTHRITIS; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; EUROPE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MOON FACE; MUSCULOSKELETAL SYSTEM; OBESITY; OSTEOPOROSIS; PRIORITY JOURNAL; SKIN; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STEROIDS; TIME FACTORS;

EID: 6544275277     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.10.953     Document Type: Article

References (22)

1. Dubois EL. Systemic lupus erythematosus: recent advances in its diagnosis and treatment. Ann Intern Med 1956;45:163-84.
2. Dubois EL. Effect of LE cell test on clinical picture of systemic lupus erythematosus. Ann Intern Med 1953;38: 1265-94.
3. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. J Am Med Assoc 1964; 190:140-51.
4. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 1971;50:85-95.
5. Drenkard C, Villa AR, Garcia-Padilla C, Perez-Vasquez ME, Alarcon-Segovia D. Remission of systemic lupus erythematosus. Medicine 1995;75:88-98.
6. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Chang CH et al. Cross-cultural validation and reliability of three disease activity indices in SLE. J Rheumatol 1992;19:608-11.
7. Bombardier C, Gladman DD, Urowitz MB, Charron D, Chang CH. The development and validation of the SLE disease activity index (SLE DAI). Arthritis Rheum 1992;35:630-40.
8. Gladman DD, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M et al. The development and initial validation of the Systemic International Collaboratory Clinics/ American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39:363-9.
9. Swaak AJG. Clinical features of systemic lupus erythematosus patients with a disease duration of > 10 years. In: Bijlsma JWJ, van der Linden SM, eds. Rheumatology highlights 1995. Amsterdam, 1995;24:223-5.
10. Swaak AJG, Nossent JC, Bronsveld W, van Rooyen A, Nieuwenhuys EJ, Theuns L et al. Systemic lupus erythematosus I. Outcome and survival. Dutch experience with 110 patients studied perspectively. Ann Rheum Dis 1989;48:447-54.
11. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
12. Bombardier C, Gladman DD, Urowitz MB, Cacon D, Chang CH. Derivation of SLE DAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
13. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Scuito M et al. Disease activity in systemic lupus erythematosus: report of the consensus study group of the European workshop for rheumatology research. II Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992;10:541-7.
14. Urowitz MB. Late mortality and morbidity. In: Proceedings of the Second International Conference on Systemic Lupus Erythematosus, Singapore. Tokyo: Professional Postgraduate Services, K.K. 1989:190-3.
15. Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chron Dis 1955;1:12.
16. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987;14(suppl. 137):223.
17. Urowitz MB. Late mortality and morbidity. In: Proceedings of the Second International Conference on Systemic Lupus Erythematosus, Singapore. K.K. Tokyo: Professional Postgraduate Services, 1989:190.
18. Ward MM, Puyn E, Studenski S. Long term survival in systemic lupus erythematosus patient: characteristics associated with poorer outcomes. Arthritis Rheum 1985;38: 274-83.
19. Cervera R, Kamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine 1993;72:113-24.
20. Gladman DD, Urowitz MB, Gorgh OJ, MacKinnon A. Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol 1996;14:305-8.
21. Swaak AJG, Nossent JC, Bronsveld W, Van Rooyen A, Nieuwenhuys EJ, Theuns L et al. Systemic lupus erythematosus II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 100 patients studied prospectively. Ann Rheum Dis 1989; 48:455-60.
22. Drenkard C, Villa AR, Garcia-Padilla C, Perez-Vazquez ME, Alarcon-Segovia D. Remission of systemic lupus erythematosus. Medicine 1996;75:88-98.